Session Information
The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.
Date: Thursday, April 30, 2020
Title: Poster Session 1
Session Type: ACR Abstract Session
Session Time: 6:00PM-7:00PM
Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is a systemic autoimmune/inflammatory disease. Up to 80% of patients develop lupus nephritis (LN) that affects treatment and prognosis(1-3). Easily accessible biomarkers do not exist to reliably predict and/or measure renal disease in jSLE, leaving kidney biopsies as the gold-standard for the diagnosis of LN. Calcium-binding S100 proteins are expressed by innate immune cells and epithelia and have been suggested as biomarkers in paediatric systemic inflammatory conditions(4-6).
Methods: We quantified serum and urine levels of S100A4 (ELISA), S100A8/A9, and S100A12 (MSD technology) in patients with jSLE, matched healthy and inflammatory (IgA vasculitis) controls.
Results: Serum S100A8/A9, and serum and urine S100A12 protein levels are increased in jSLE patients when compared to controls. Furthermore, serum S100A8/A9, and serum and urine S100A12 protein levels are increased in jSLE patients with active LN as compared to patients with inactive or no renal disease. We did not detect differences in S100A4 levels between patient groups (jSLE, IgA vasculitis) and controls or jSLE patients with vs without active LN.
Conclusion: Findings from this study promise potential for S100A8/A9 and S100A12 as biomarkers for jSLE and active LN. Findings require to be confirmed and tested prospectively in independent and larger multi-ethnic cohorts.
References:
- Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, et al. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum. 2012;64(7):2356-65.
- Tucker LB, Uribe AG, Fernandez M, Vila LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314-22.
- Morgan T, Watson L, McCann L, Beresford M. Children and adolescents with SLE: not just little adults:. http://dxdoiorg/101177/0961203313502863. 2013.
- Kessel C, Holzinger D, Foell D. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol. 2013;147(3):229-41.
- Turnier JL, Fall N, Thornton S, Witte D, Bennett MR, Appenzeller S, et al. Urine S100 proteins as potential biomarkers of lupus nephritis activity. Arthritis Res Ther. 2017;19(1):242.
- Holzinger D, Frosch M, Kastrup A, Prince FH, Otten MH, Van Suijlekom-Smit LW, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71(6):974-80.
To cite this abstract in AMA style:
Donohue S, Midgley A, Davies J, Wright R, Bruce I, Beresford M, Hedrich C. Differential Analysis of Serum and Urine S100 Proteins in Juvenile-onset Systemic Lupus Erythematosus (jSLE) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/differential-analysis-of-serum-and-urine-s100-proteins-in-juvenile-onset-systemic-lupus-erythematosus-jsle/. Accessed .« Back to 2020 Pediatric Rheumatology Symposium
ACR Meeting Abstracts - https://acrabstracts.org/abstract/differential-analysis-of-serum-and-urine-s100-proteins-in-juvenile-onset-systemic-lupus-erythematosus-jsle/